FDA
-
-
-
-
-
-
-
Silo Pharma files patent for ibogaine treatment targeting brain injury
-
-
-
-
-
-
-
Silo Pharma signs letter of intent with Allucent for phase 1 studies
-
-
-
-
-
-
-
Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
-
-
-
-
-
-
-
Silo Pharma completes dosing in PTSD drug safety study
-
-
-
-
-
-
-
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
-
-
-
-
-
-
-
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
-
-
-
-
-
-
-
Silo Pharma (SILO) Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26
-
326,426 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

